Director

Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms. 

 Senior Director, Multiomics – Ginkgo Datapoints

Level (Sr. Director) will be set to match the successful candidate's experience.

Location: Boston, MA (Seaport / HQ) Reporting to: General Manager, Ginkgo Datapoints Focus: Scientific Excellence, Commercial Strategy (P&L), Functional Genomics, Arrayed Perturbation Response Profiling & Multiomic Platform Expansion

The Opportunity

Ginkgo Datapoints defines the category of the Bio × AI data provider. We work with top pharma, biotech, tech, and techbio companies, and we've built our reputation on high-quality, large-scale, reproducible data generated by automation rather than by hand. We're a fee-for-service partner — our customers own their data, and our incentives are aligned with theirs.

As our Senior Director of Multiomics, you will own the vision, execution, and commercial success of our Multiomics business, including the functional genomics engine behind our Perturbation Response Profiling and Specialized HTS offerings. This is a genuinely intrapreneurial role: you operate at the frontier of business and science, report to the GM of Datapoints, and lead a multidisciplinary team of scientists, automation engineers, and bioinformaticians with GS&A support.

Your Mission

Your primary goal is to scale our arrayed multiomic perturbation platform into the best in the industry, and to own the full P&L for the vertical. The near-term growth thesis is clear:

• Find new applications for DRUG-seq — safety first. Expand our high-throughput transcriptomic screening into new use cases, with safety and predictive toxicology chief among them.

• Turn perturbation data into AI fuel. Position our datasets as the training substrate for the next generation of AI/ML models, and shape data generation specifically to serve model training.

• Round out the readout menu. Extend beyond transcriptomics and imaging into proteomics, metabolomics, and additional NGS methods that complete a true multiomic offering.

• Build products the industry doesn't have yet. Add new offerings to the portfolio — arrayed whole-genome CRISPR knockouts paired with rich multiomic readouts among them — and the drug-discovery power that kind of capability unlocks.